Table of Contents Author Guidelines Submit a Manuscript
Depression Research and Treatment
Volume 2012, Article ID 815363, 8 pages
http://dx.doi.org/10.1155/2012/815363
Research Article

Predictors of Treatment with Duloxetine or Venlafaxine XR among Adult Patients Treated for Depression in Primary Care Practices in the United Kingdom

1Thomson Reuters, Cambridge, MA 02140, USA
2Thomson Reuters, Washington, DC 20008, USA
3General Electric Healthcare, 2 Bethesda Metro Center, Bethesda, MD 20814, USA
4Eli Lilly and Company, Health Technology Appraisal Group, 61352 Bad Homburg, Germany

Received 5 January 2012; Revised 14 March 2012; Accepted 1 April 2012

Academic Editor: Charles B. Nemeroff

Copyright © 2012 Nianwen Shi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Knowledge about real-world use of duloxetine and venlafaxine XR to treat depression in the UK is limited. Aims. To identify predictors of duloxetine or venlafaxine XR initiation. Method. Adult depressed patients who initiated duloxetine or venlafaxine XR between January 1, 2006 and September 30, 2007 were identified in the UK’s General Practice Research Database. Demographic and clinical predictors of treatment initiation with duloxetine and venlafaxine XR were identified using logistic regression. Results. Patients initiating duloxetine (n=909) were 4 years older than venlafaxine XR recipients (n=1286). Older age, preexisting unexplained pain, respiratory disease, and pre-period use of anticonvulsants, opioids, and antihyperlipidemics were associated with increased odds of initiating duloxetine compared to venlafaxine XR. Pre-period anxiety disorder was associated with decreased odds of receiving duloxetine. Conclusion. Initial treatment choice with duloxetine versus venlafaxine XR was primarily driven by patient-specific mental and medical health characteristics. General practitioners in the UK favor duloxetine over venlafaxine XR when pain conditions coexist with depression.